Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Quanterix ( (QTRX) ) just unveiled an update.
On September 29, 2025, Quanterix Corporation held its Annual Meeting of Stockholders, where several key proposals were approved. These included the election of three independent directors, approval of executive compensation, ratification of KPMG as the accounting firm, and amendments to the company’s Charter to declassify the board and eliminate supermajority voting requirements. These changes are expected to streamline governance and potentially enhance shareholder influence in corporate decisions.
The most recent analyst rating on (QTRX) stock is a Hold with a $5.50 price target. To see the full list of analyst forecasts on Quanterix stock, see the QTRX Stock Forecast page.
Spark’s Take on QTRX Stock
According to Spark, TipRanks’ AI Analyst, QTRX is a Neutral.
Quanterix’s overall stock score is primarily impacted by its challenging financial performance, with declining revenues and persistent losses. Technical analysis suggests a bearish trend, and valuation metrics indicate limited immediate return potential. While the earnings call provided some positive long-term strategic insights, the current financial challenges remain significant.
To see Spark’s full report on QTRX stock, click here.
More about Quanterix
Quanterix Corporation operates in the biotechnology industry, focusing on developing ultra-sensitive digital immunoassay technology. The company’s primary products and services include advanced diagnostic tools that enable the detection of biomarkers for various diseases, with a market focus on enhancing precision health.
Average Trading Volume: 661,138
Technical Sentiment Signal: Sell
Current Market Cap: $257.4M
For detailed information about QTRX stock, go to TipRanks’ Stock Analysis page.